Menopause is the cessation of menstruation and reproductive function, due to reduced ovarian activity. Menopause typically occurs between 45 and 55 years of age. Androgens are natural steroid hormones regulating the development and maintenance of classically male characteristics. However, women also depend on the physiological action of androgens which are thought to include regulation of libido and sexual arousal.
| INTRODUC TI ON
Menopause is the cessation of menstruation and reproductive function, due to reduced ovarian activity. Menopause typically occurs between 45 and 55 years of age. 1 Reduced circulating levels of oestrogen during menopause transition or perimenopause may cause hot flushes, low mood and symptoms of vulvovaginal atrophy. 2 The hallmark symptoms of menopausal transition/perimenopause are hot flushes and irregular periods, whereas amenorrhoea is required for menopause itself.
Women may experience vaginal atrophy and vaginal dryness mostly in the late menopausal transition and even beyond. [2] [3] [4] Some women also experience decreased libido, receptivity and responsiveness, and reduced frequency of sexual thoughts and fantasies during menopause transition and postmenopause. It is estimated that 50%-60% of all postmenopausal women suffer from symptoms of urogenital and sexual dysfunction. 5, 6 Androgens are natural steroid hormones regulating the development and maintenance of classically male characteristics. However, women also depend on the physiological action of androgens which are thought to include regulation of libido and sexual arousal. 7 Androgens are synthesized in the testes, ovaries and adrenal glands. 8 It is over 60 years since testosterone therapy was first reported in postmenopausal women. 9 There is currently growing interest in the role of testosterone therapy for the treatment of sexual dysfunction in postmenopausal women; however, prescribing behaviour is highly variable across the UK, which reflects uncertainty about the safety and effectiveness of therapy. This article aims to provide an objective summary of the evidence to date investigating the effectiveness and safety of testosterone replacement for sexual dysfunction in postmenopausal women.
| MATERIAL S AND ME THODS

| Search and selection
A search of the electronic databases CENTRAL, EMBASE, MEDLINE and PubMed was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement during July 2018 10 (See Table S1 ). All studies identified using search terms up until July 2018 were considered for inclusion to the study. Databases were searched using the following terms: "female OR females OR women OR woman,"
AND "postmenopausal OR postmenopausal OR postmenopause OR postmenopause OR perimenopausal OR peri-menopausal OR perimenopause OR peri-menopause OR climacteric" AND "testosterone" AND "placebo OR placebos OR random OR randomised OR randomized OR randomly OR randomly allocated." Identified studies were excluded if the abstracts were not in the English language, or included purely pharmacokinetic outcomes. For studies to be included, subjects were required to be perimenopausal or postmenopausal women presenting with symptoms of sexual dysfunction, dyslipidaemia, impaired memory, decreased bone mineral density or breast symptoms. One study was excluded because all subjects had rheumatoid arthritis. 
| Data extraction
Study titles and abstracts were initially screened before full-text review was completed in duplicate by two study investigators (CSL and CNJ). Discrepancies were dealt with by consensus. A total of 69 studies fulfilled the criteria for inclusion to this systematic review ( Figure 1 ). Data identified for all studies were as follows: date of publication; intervention administered; blinding; randomization; treatment duration; allocation; route of administration and treatment dosage; number of subject participants; design of the study, study references and source of funding.
| ANDROG EN S AND THEIR ROLE IN S E XUAL FUN C TION
Oestrogens are the dominant sex hormones required for female reproductive maturation and activity. However, androgens also play a biological role in women. Further, in premenopausal women, circulating T and E2 have similar picomolar concentrations. The major androgens in the serum of normal cycling women are dehydroepiandrosterone sulphate (DHEAS), dehydroepiandrosterone (DHEA),
androstenedione, testosterone and dihydrotestosterone (DHT).
Though abundant in the circulation, DHEAS, DHEA and androstenedione may be considered pro-hormones, requiring conversion to testosterone or DHT to express their androgenic effects. 12 As testosterone requires conversion to E2 or DHT to express its biological effects, it too can be considered a pro-hormone in males and females.
The ovaries and the adrenal glands are the major sources of androgen synthesis in women. Testosterone is the major ovarian androgen, and dehydroepiandrosterone (DHEA) is the major adrenal androgen. 13 Androgen hormones circulate in the blood stream bound to carrier proteins such as sex hormone binding globulin (SHBG) and albumin and corticosteroid binding globulin. Circulating testosterone is highly bound to plasma proteins, with about 66%
bound to SHBG and 33% to albumin. SHBG weakly binds DHEA but not DHEAS. [14] [15] [16] Androgens exert biological effects by activating androgen receptors (AR), and indirectly by conversion to oestrogen via aromatization. Androgen receptors are located in several organs of the body, including breast, brain, ovaries, bone, muscle, fat, liver and skin. 17 Moreover, testosterone is known to have multiple anabolic F I G U R E 1 PRISMA chart summarising search strategy for the systematic review effects on muscles, body fat and bone mineral content in women. 18 Androgens are likely to influence behaviour through organizational or activational effects on the brain, which may be either directly, or indirectly mediated through aromatization to oestrogen. 19 It is also important to recognize that effects of sex hormones on sexual function, sexual thoughts and behaviour may be (at least partially) mediated indirectly through improved vaginal lubrication. 20 Of relevance in men, penile injury following intercourse reduces libido, and circumcision to prevent future penile injury is associated with recovery of libido.
21
A cross-sectional study of 1423 women between the ages of 18 and 75 suggested total testosterone measured via radioimmunoassay, calculated free testosterone, dehydroepiandrosterone sulphate and androstenedione declined steeply in the early reproductive years and do not vary as a consequence of natural menopause, and the postmenopausal ovary seems to be an ongoing site of testosterone production. 22, 23 It is however important to highlight that there are many limitations using immunoassays to measure testosterone in women; this is due to limited accuracy and sensitivity at low concentrations of total testosterone when compared with mass spectrometry. 24 Some studies measuring serum androgen levels in premeno- Data correlating androgen levels with specific signs or symptoms are unavailable. Consequently, the American Endocrine Society 28 recommends against making the diagnosis of androgen deficiency in women. In summary, it is accepted that androgens may influence sexual behaviour, but it is unclear whether a reduction in endogenous androgen production contributes to sexual dysfunction during the postmenopause.
The 11-ketotestosterone (11 KT) and 11-ketodihydrotestosterone (11KDHT) are androgen derivatives of the adrenal steroid precursor, 11β-hydroxyandrostenedione (11OHA4). Both 11 KT and 11KDHT are potent agonists of the human androgen receptor (AR). Studies are required to investigate whether levels of 11 KT and 11KDHT are significantly related to sexual function in women during menopause transition. 29 
| THE D IAG NOS IS AND PRE VALEN CE OF S E XUAL DYS FUN C TI ON IN MENOPAUSAL WO MEN
A number of previous studies have investigated the prevalence of sexual dysfunction in menopausal women using structured ques- inhibition prevents testosterone administration from improving libido in GnRH agonist-induced hypogonadism. 51 Finally, it would be helpful to specifically investigate whether the testosterone therapy improves sexual function in postmenopausal women whose serum oestradiol levels are replete (eg, serum E2 levels 300-600 pmol/L) during HRT; this would suggest that testosterone is not simply acting to supplement bodily oestrogen exposure (via aromatization).
| EFFEC TS OF TE S TOS TERONE SUPPLEMENTATI ON ON S E XUAL FUN C TI ON
| Other routes of testosterone administration
Recent clinical trials have investigated the administration of nontransdermal application of testosterone in postmenopausal women.
Urogenital topical application was investigated in 75 menopausal
women (natural or surgical), who were randomized to placebo, oestrogen only or oestrogen with testosterone over a 12-week period. Significant increase in PFSF with T compared to placebo (P = 0.02) 43% increase in weekly frequency of SSE at 24 wk for T vs placebo (P = 0.06) Significant reduction in PDS with T vs placebo (P = 0.003) Significant increase in sexual arousal (P = 0.02), orgasm (P = 0.03), sexual responsiveness (P = 0.005), sexual self-image (P = 0.04), lessening of sexual concerns (P = 0.003) and increase in PGWB (P = 0.04) with T vs placebo. Significant increase in BMD for total body (P < 0.008), vertebral L1-L4 (P < 0.001) and trochanteric BMD (P < 0.05) with T compared to E2 alone. E2 + T greater increase in sexuality: activity (P < 0.03), pleasure (P < 0.01), orgasm (P < 0.035) and relevancy (P < 0. In another double-blinded randomized study by Huang et al, 56 71 menopausal women who previously underwent hysterectomy with or without oophorectomy received a standardized transdermal oestrogen regimen during the 12-week run-in period, and were then randomized to receive weekly IM injections of placebo, or 3, 6.25, 12.5 or 25 mg testosterone enanthate for 24 weeks. Dose-dependent improvements in several domains of sexual function, lean body mass, chest-press power and loaded stair-climb power were observed, with the greatest improvements at the highest dose. Furthermore, a double-blind randomized study by Dobs and colleagues, with 40 naturally and surgically menopausal women, observed significant increases in upper and lower body strength with testosterone compared to placebo. 57 Whilst the majority of studies observed testosterone significantly increased sexual arousal/interest, 39,42,52,57,58 frequency of orgasms 13, 39, 57 and frequency of sexual activity 13, 47, 52 when compared to placebo, some suggest no significant difference between the treatment groups. 39, [58] [59] [60] [61] In conclusion, most but not all studies suggest that testosterone improves symptoms of sexual dysfunction regardless of the route of administration.
Further studies are required to investigate whether the observed effects of testosterone administration on sexual function are truly dose dependent. FFM increased significantly (P < 0.01), whereas FM:FFM ratio declined (P < 0.05) with T, but not with E2 alone. Significant decrease in hip and abdominal circumference (P < 0.01, P < 0.05 respectively) with E2 alone.
Yes
For studies to be included, subjects were required to be perimenopausal or postmenopausal women presenting with symptoms of sexual dysfunction, dyslipidaemia, impaired memory, decreased bone mineral density or breast symptoms. BISF-W, brief index of sexual functioning for women; CSFQ-F-C, changes in sexual functioning questionnaire; FSFI, female sexual function index; McCoy, McCoy female sexuality questionnaire; PFSF, profile of female sexual function; PGWB, psychological general well-being scale; SAL, sexual activity log; SSEs, satisfying sexual episodes; SSSS, Sabbatsberg sexual self-rating scale; WHQ, women's health questionnaire. TA B L E 2 (Continued)
| NON S E XUAL EFFEC TS OF TE S TOS TERONE THER APY
Testosterone therapy is anticipated to cause symptoms of androgen excess such as excess body hair (hirsutism) and acne. Accordingly, clinical trials reported that the most common adverse effects associated with testosterone therapy were skin reactions, unwanted hair growth, acne and vaginal bleeding; however, most were mild and rarely resulted in withdrawal from the study. 18, 44, 46, 50, 52, 57, [62] [63] [64] [65] Furthermore, two published studies observed no significant difference in adverse effects between treatment groups.
66,67
| Breast cancer risk
Exogenous sex steroids may stimulate the growth of sexhormone dependent tissues, most notably breast tissue in women, 68, 69 so it is relevant to consider whether testosterone therapy increases the risk of breast cancer. The only published long-term investigation of testosterone therapy in postmenopausal women has been conducted by the product's manufacturer. 57 Overall, whilst studies agree that testosterone has no effect on BMI, there is no consensus on its effects on fat mass in the absence of longterm large scale trials.
| Endometrial effects
| Bone mineral density
| Cognitive function
The effects of steroid hormones on human cognition are of con- 106 In summary, studies published to date have observed a variety of effects on cognition following testosterone therapy; it is therefore difficult to draw conclusions on the predicted effects of testosterone in postmenopausal women.
| Physical symptoms
A 2002 study by Dobs and colleagues gave esterified oestrogens with or without methyltestosterone to 40 naturally and surgically menopausal women and observed testosterone significantly improved both somatic and vasomotor symptoms compared to oestrogen alone. 57 However, the majority of studies seem to agree testosterone therapy has no significant beneficial effect on suppressing hot flash frequency and severity. 58, 64, 67, 107 A further study observed no significant improvement in somatic or psychological symptoms with testosterone compared to placebo 58 whilst another observed no significant difference in sweating and vaginal dryness between treatment groups. 67 In summary, most studies suggest that testosterone does not affect menopausal hot flushes and it remains to be determined whether somatic symptoms or vaginal dryness is altered during testosterone therapy.
| LIMITATI ON S OF DATA
Currently, there is limited long-term data evaluating whether testosterone replacement increases the risks of cardiovascular disease, or breast cancer. In view of the controversy regarding the safety of testosterone therapy in older men (albeit when administered at much higher doses), 108 a similarly cautious approach might be appropriate for postmenopausal women with risk factors for cardiovascular disease or breast cancer. It is also important to consider that many of the clinical trials performed to date have been industry funded. It is plausible that reporter bias might have skewed the published literature towards studies supporting the usage of testosterone in postmenopausal women; future, academic-sponsored studies are needed to address this concern. Finally, to fulfil the criteria for HSDD or Female sexual dysfunction, selected study participants were screened to exclude disease comorbidities. It is, therefore, not known whether postmenopausal women with disease comorbidities would also benefit from testosterone therapy.
This limits the extent to which published data may reflect everyday clinical practice.
| CON CLUS ION
Sexual dysfunction is a common problem in postmenopausal women, which may profoundly affect quality of life. Endogenous testosterone may influence sexual behaviour in women. However, there is a lack of evidence implicating deficient endogenous testosterone in the evolution of sexual dysfunction in women. Furthermore, there is considerable variation in the prevalence of menopause-related sexual dysfunction, depending on the criteria employed. Several randomized, placebo-controlled clinical trials suggest that testosterone therapy significantly improves sexual function assessed using validated questionnaires, in postmenopausal women with sexual dysfunction or hypoactive sexual desire disorder. The effect size is modest, with approximately one additional satisfactory sexual activity per month. In the short-term, testosterone therapy is generally well tolerated and safe adverse effects predominantly consist of localized skin reactions and cosmetic effects of hyperandrogenaemia.
Possible impacts on lipid metabolism, cardiovascular and cancer risk warrant further detailed investigations, although no major safety concerns have been raised to date. In line with the US Endocrine Society Clinical Practice Guidelines, there is currently insufficient evidence regarding general recommendations for testosterone therapy in women. 28 There are also no licensed products in the UK for female administration of testosterone; testosterone preparations designed to administer much higher doses (to men) must therefore be used. If clinicians are considering offering this treatment to postmenopausal women, it is necessary to provide full counselling on the risks and benefits, particularly the limited effect of testosterone and the lack of long-term safety data. However with these caveats, there is sufficient evidence to recommend testosterone therapy for the minority of postmenopausal women for whom other management strategies have failed.
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